)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
NATCO Pharma
NATCO Pharma (NATCOPHARM) investor relations material
NATCO Pharma Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary14 Aug, 2026
Executive summary
Consolidated Q1 FY27 revenue was INR 7,944 million, down from INR 13,906 million year-over-year, mainly due to lower Lenalidomide sales, partially offset by double-digit growth in the base business.
EBITDA for the quarter was INR 2,457 million with a margin of 30.9%, showing improvement from 25.1% in Q4 FY26 due to better international and domestic performance and controlled costs.
Profit after tax (PAT) was INR 2,065 million, with a margin of 26%, compared to INR 4,803 million in Q1 FY26; normalized PAT grew 34% sequentially.
Strong performance from associate Adcock Ingram (South Africa), with share of profit at INR 843 million; stake increased to 49% in July 2026.
Interim dividend of INR 1.50 per equity share declared for Q1 FY27.
Financial highlights
Brazil revenue grew 180% year-over-year to INR 178 crores.
Domestic formulation revenue was INR 1,364 million, with base business rising to INR 1,300 million, driven by semaglutide and oncology.
Canada sales for the quarter were INR 56 crores.
International formulations revenue was INR 4,771 million, with a quarter-on-quarter decline attributed to seasonality and product cycles.
Earnings per share for Q1 FY27 was INR 11.53.
Outlook and guidance
Domestic business expected to grow 25% in volumes for FY27.
PAT guidance remains at INR 750 crores for FY27, with management cautioning against extrapolating Q1's seasonal profit bump.
Crop Health Sciences expected to break even for the year, with Q2 anticipated as the strongest quarter.
Full-year gross sales guidance is INR 33-34 billion.
Pipeline includes 28 Para IVs in the US, with over 20 first-to-file opportunities and 17 products with tentative or full approval.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from NATCO Pharma
- Record FY24 profit growth was led by Pharmaceuticals, partly offset by Agro chemicals losses.NATCOPHARM
Q4 23/24 - FY26 saw robust growth, global expansion, and innovation in complex generics and advanced therapies.NATCOPHARMInvestor presentation
- FY26 revenue and profit declined, but new launches and acquisitions support future growth.NATCOPHARMQ4 25/26
- Q3FY26 revenue and profit rose, driven by pharma growth, exports, and a key South African acquisition.NATCOPHARMQ3 25/26
- Q2FY26 saw INR 1,463 crore revenue, INR 517.9 crore profit, and a INR 1.5 interim dividend.NATCOPHARMQ2 25/26
- Profit and EPS declined on higher costs and impairment, but cash and pipeline remain strong.NATCOPHARMQ1 25/26
- Q2 FY25 revenue and net profit surged on export growth, strong margins, and a positive outlook.NATCOPHARMQ2 24/25
- Net profit surged 59% in Q1 FY25 on strong export formulations and Revlimid growth.NATCOPHARMQ1 24/25
- Q3 FY25 profit and revenue fell, but new launches and a dividend signal optimism ahead.NATCOPHARMQ3 24/25
Next NATCO Pharma earnings date
Q2 26/2713 Nov, 2026
NATCO Pharma
Next NATCO Pharma earnings date
Q2 26/2713 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
NATCO Pharma Limited is a pharmaceutical company specializing in the development, manufacturing, and marketing of generic and specialty pharmaceuticals. The company produces a range of pharmaceutical products, including oncology, cardiology, and central nervous system medications, focusing on affordable therapies for complex health conditions. NATCO Pharma serves both domestic and international markets, providing formulations and active pharmaceutical ingredients (APIs) to healthcare providers and distributors. The company is headquartered in Hyderabad, India, and its shares are listed on the NSE and BSE.